Related Experiment Video

Updated: Aug 24, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells

Sara M E Osford1, Claire L Dallman, Peter W M Johnson

  • 1Cancer Research UK Oncology Unit, Cancer Sciences Dvision, School of Medicine, University of Southampton, Southampton General Hospital, UK.

Current Medicinal Chemistry
|April 16, 2004
PubMed

Insights

Programmed cell death, or apoptosis, is vital for development and health. Targeting the Bcl-2 protein, crucial for cancer cell survival, offers a promising strategy for new anti-cancer therapies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Apoptosis, a genetically controlled cell death pathway, is essential for development and tissue homeostasis.
  • Dysregulation of apoptosis is implicated in various diseases, including cancer, AIDS, and neurodegenerative disorders.
  • Resistance to apoptosis is a hallmark of human malignancies, contributing to cancer development and therapeutic resistance.

Purpose of the Study:

  • To review the mechanism of action and significance of Bcl-2 in cancer cells.
  • To discuss the progress in developing novel therapeutic agents targeting Bcl-2.
  • To highlight Bcl-2 as a target for molecularly directed anti-cancer strategies.

Main Methods:

  • Review of experimental data on Bcl-2 function and targeting.
  • Analysis of Bcl-2's role in cancer cell survival and resistance to apoptosis.
  • Examination of current therapeutic strategies aimed at inhibiting Bcl-2.

Main Results:

  • Bcl-2 overexpression confers resistance to apoptosis inducers.
  • Bcl-2's cell survival functions are activated by translocation in lymphomas and overexpression in other cancers.
  • Bcl-2 is a validated target for anti-cancer drug development.

Conclusions:

  • Bcl-2 is a key survival molecule in cancer cells.
  • Targeting Bcl-2 presents a promising strategy for novel anti-cancer therapies.
  • Further development of Bcl-2-targeting agents is crucial for improving cancer treatment outcomes.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...